BiotechTube

Chemotherapy + Immunotherapy Induction + Immunotherapy Maintenance

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Muscle-invasive Bladder Cancer

Conditions

Muscle-invasive Bladder Cancer

Trial Timeline

Apr 15, 2025 → Aug 15, 2028

NCT ID
NCT06686381

About Chemotherapy + Immunotherapy Induction + Immunotherapy Maintenance

Chemotherapy + Immunotherapy Induction + Immunotherapy Maintenance is a phase 2 stage product being developed by Merck for Muscle-invasive Bladder Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06686381. Target conditions include Muscle-invasive Bladder Cancer.

What happened to similar drugs?

0 of 3 similar drugs in Muscle-invasive Bladder Cancer were approved

Approved (0) Terminated (0) Active (3)
🔄Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
🔄Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3
🔄AtezolizumabRochePhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06686381Phase 2Recruiting

Competing Products

12 competing products in Muscle-invasive Bladder Cancer

See all competitors
ProductCompanyStageHype Score
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
44
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3
44
Durvalumab (Imfinzi) + TremelimumabAstraZenecaPhase 2
27
Pembrolizumab + GemcitabineMerckPhase 2
39
Autogene Cevumeran + Nivolumab + SalineRochePhase 2
42
AtezolizumabRochePhase 3
44
Nivolumab + Nab-paclitaxel + NivolumabBristol Myers SquibbPhase 2
31
Cretostimogene GrenadenorepvecCG OncologyPhase 2
39
CG0070 + NivolumabCG OncologyPhase 1
26
AU-011Aura BiosciencesPhase 1
26
REOLYSIN® + Gemcitabine + CisplatinOncolytics BiotechPhase 1
11